Similar articles for PMID: 29995236

Year	Number of Results
1995	1
2002	1
2003	1
2009	1
2010	1
2011	2
2013	1
2014	1
2015	9
2016	26
2017	66
2018	112
2019	112
2020	61
2021	38
2022	27
2023	8
2024	0

1

Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC.

Matsuura N, Koh G, Konishi C, Minamino S, Takahara Y, Harada H, Kodama K, Emoto M. Matsuura N, et al. Cancer Immunol Immunother. 2018 Sep;67(9):1417-1424. doi: 10.1007/s00262-018-2203-3. Epub 2018 Jul 11. Cancer Immunol Immunother. 2018. PMID: 29995236

2

Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.

Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, Veloski C. Godwin JL, et al. J Immunother Cancer. 2017 May 16;5:40. doi: 10.1186/s40425-017-0245-2. eCollection 2017. J Immunother Cancer. 2017. PMID: 28515940 Free PMC article.

3

Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.

Yilmaz M. Yilmaz M. J Oncol Pharm Pract. 2020 Jan;26(1):236-239. doi: 10.1177/1078155219841116. Epub 2019 Apr 7. J Oncol Pharm Pract. 2020. PMID: 30955467

4

Nivolumab-induced acute-onset type 1 diabetes mellitus as an immune-related adverse event: A case report.

Hatakeyama Y, Ohnishi H, Suda K, Okamura K, Shimada T, Yoshimura S. Hatakeyama Y, et al. J Oncol Pharm Pract. 2019 Dec;25(8):2023-2026. doi: 10.1177/1078155218816777. Epub 2018 Dec 8. J Oncol Pharm Pract. 2019. PMID: 30526346

5

A Patient with Nivolumab-related Fulminant Type 1 Diabetes Mellitus whose Serum C-peptide Level Was Preserved at the Initial Detection of Hyperglycemia.

Yamamoto N, Tsurutani Y, Katsuragawa S, Kubo H, Sunouchi T, Hirose R, Hoshino Y, Ichikawa M, Takiguchi T, Yukawa H, Arioka H, Saitou J, Nishikawa T. Yamamoto N, et al. Intern Med. 2019 Oct 1;58(19):2825-2830. doi: 10.2169/internalmedicine.2780-19. Epub 2019 Jun 27. Intern Med. 2019. PMID: 31243198 Free PMC article.

6

Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.

Oyanagi J, Koh Y, Sato K, Mori K, Teraoka S, Akamatsu H, Kanai K, Hayata A, Tokudome N, Akamatsu K, Nakanishi M, Ueda H, Yamamoto N. Oyanagi J, et al. Lung Cancer. 2019 Jun;132:107-113. doi: 10.1016/j.lungcan.2019.03.020. Epub 2019 Mar 22. Lung Cancer. 2019. PMID: 31097082

7

Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.

Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z. Sakurai K, et al. Tohoku J Exp Med. 2018 Jan;244(1):33-40. doi: 10.1620/tjem.244.33. Tohoku J Exp Med. 2018. PMID: 29343652 Free article.

8

[Effectiveness of a Low-dose Corticosteroid in a Patient with Polymyalgia Rheumatica Associated with Nivolumab Treatment].

Imai Y, Tanaka M, Fujii R, Uchitani K, Okazaki K. Imai Y, et al. Yakugaku Zasshi. 2019;139(3):491-495. doi: 10.1248/yakushi.18-00161. Yakugaku Zasshi. 2019. PMID: 30828027 Free article. Japanese.

9

Nivolumab-induced fulminant type 1 diabetes with precipitous fall in C-peptide level.

Miyauchi M, Toyoda M, Zhang J, Hamada N, Yamawaki T, Tanaka J, Harada K, Kashizaki F, Fukagawa M. Miyauchi M, et al. J Diabetes Investig. 2020 May;11(3):748-749. doi: 10.1111/jdi.13143. Epub 2019 Oct 6. J Diabetes Investig. 2020. PMID: 31587459 Free PMC article.

10

Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes.

Miyoshi Y, Ogawa O, Oyama Y. Miyoshi Y, et al. Tohoku J Exp Med. 2016 Jun;239(2):155-8. doi: 10.1620/tjem.239.155. Tohoku J Exp Med. 2016. PMID: 27297738 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

401 results

Results by year